Efficacy and Safety of Datopotamab Deruxtecan in Patients with Pretreated Advanced/Metastatic NSCLC with Actionable Genomic Alterations By Ogkologos - January 27, 2025 460 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TROPION-Lung05 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Honoring our Labor September 1, 2021 Alternatives for Outdoor Foods October 16, 2020 Analysis Patterns of Systemic Anticancer Treatment at End-of-Life Indicates No Changes... November 2, 2022 Different Microbiota–Host Relationships Relevant to Distinct Immune Checkpoint Blockade Regimens March 21, 2024 Load more HOT NEWS ESMO Welcomes EU Proposals for MFF & FP10 and Calls for... Efficacy of Talquetamab Plus Teclistamab in Patients with Extramedullary Myeloma Why the voices of people affected by cancer are critical to... An Intensive Follow-Up in Surgically Treated Patients for Endometrial Cancer Does...
